Neuroendocrine tumors originate from neuroendocrine cells, often presenting as slower-growing compared to other cancers like adenocarcinomas. Diagnosing NETs is challenging due to varied symptoms and ...

Cabometyx is now approved for advanced pancreatic and extra-pancreatic NETs, offering a new treatment option for these patients. The phase 3 CABINET trial showed Cabometyx significantly improved ...

Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study The mammalian target of rapamycin (mTOR) ...

Neuroendocrine cells are unique in their ability to act both as nerve cells and hormone-making cells. They're scattered throughout the body, including the stomach, intestines, pancreas and lungs.

Cabozantinib improves progression-free survival (PFS) in patients with advanced extrapancreatic neuroendocrine tumors and pancreatic neuroendocrine tumors compared with placebo. Cabozantinib, an oral ...

The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic ...

Quality of life in patients with gastroenteropancreatic neuroendocrine tumors receiving 177Lu-edotreotide or everolimus: Results from the COMPETE study. Cohort-level safety and efficacy results for ...

The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their ...

Nuclear medicine is being called a new frontier in cancer care, and new research shows potential new uses for it in treating gastric and pancreatic cancers. Nuclear medicine that uses radioactive ...